Home > Ethics
* * * *
* * * *
* > HCS home *
* * * *
* * * *
* * * *
* > SWE Login *
* * * *
* * * *
* * * *
* > About Us *
* * * *
* * * *
* * * *
* > Consortium Members *
* * * *
* * * *
* * * *
* > Contacts *
* * * *
* * * *
* * * *
* > Delivery *
* * * *
* * * *
* * * *
* > Capability *
* * * *
* * * *
* * * *
* > Knowledge Management *
* * * *
* * * *
* * * *
* > HSCLifecycle *
* * * *
* * * *
* * * *
* > Ethics *
* * * *
* * * *
*

Ethics

Important Letter to Consortium Members

This page provides links to documents and information on a number of research ethics issues that are important for H–SC members conducting human science research under the Preparing People for Operations contract for the MoD.

It is important that all consortium members read the attached letter (hard copies of which will be sent to all partners). Link to important letter to Consortium members
*


Ethics

All trials involving human subjects carried out by the Haldane-Spearman Consortium must be approved by the QinetiQ Ethics Committee and the MoD Research Ethics Committee. This applies to all trials or field studies involving human subjects conducted under the Preparing People for Operations Enabling Agreement.

A trial in this instance is defined as any study, trial or experiment that involves the participation of human subjects or volunteers.

The documentation contained in this site will help guide you through the rationale and procedures required to write and submit a protocol to obtain approval to undertake a trial on human subjects. Further information can be obtained from the Programme Manager or Technical Director of the Haldane Spearman Consortium.

The following documents are currently available:

· Procedures covered by EGAP (Ethical Guidelines: Approved Procedures)

· The Declaration of Helsinki

· JSP 536 (Ethical Conduct and Scrutiny in MoD Research Involving Human Participants)

· Definition of Type B trials

· Link to MoD Research Ethics Committee
*
*
*
* Supporting information
*
> Procedures covered by EGAP [PDF]
> The Declaration of Helsinki [PDF]
> JSP 536 [PDF]
> Definition of Type B trials [PDF]
> Important Letter to Consortium Members [PDF]
*
*
*
* *
*		 *
 
      Cookie Policy | Conditions of use | Copyright information © Haldane-Spearman Consortium 2005
 
QinetiQ Group plc,  Company Registration No 4586941,  Registered office 85 Buckingham Gate, London SW1E 6PD